Physician profile
Daniel B Lord
NPI 1245224344
$4,074.63
in general payments reported to CMS, 2019-2025
35 companies · $487 in 2025
The $487 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $536 · 2021: $689 · 2022: $719 · 2023: $799 · 2024: $388 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570 · Gift: $79.69 · Education: $24.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.15 |
| Gift | $79.69 |
| Education | $24.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,188.04 | 2019-2025 | |
| Pfizer INC. | $529.76 | 2019-2025 | |
| Braintree Laboratories, INC. | $484.64 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $215.57 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $171.68 | 2019-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $166.22 | 2019-2024 | Entyvio |
| Redhill Biopharma INC. | $126.23 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $122.13 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.49 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $95.42 | 2019-2024 | Tremfya |
| Celgene Corporation | $75.88 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $70.06 | 2019-2021 | |
| Qol Medical, LLC | $63.58 | 2021-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $62.46 | 2020-2023 | Dificid |
| Medtronic, INC. | $60.11 | 2024-2025 | Gi Genius, Pillcam |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $52.56 | 2025 | Rezdiffra |
| Amgen INC. | $52.56 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $51.28 | 2020-2021 | |
| Ardelyx, INC. | $44.30 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $43.73 | 2024-2025 | Iqirvo, Bylvay |
| Evoke Pharma, INC. | $30.37 | 2023-2024 | Gimoti |
| Genzyme Corporation | $28.78 | 2023 | |
| Gilead Sciences, INC. | $27.32 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $25.82 | 2022 | |
| Celltrion USA INC. | $24.42 | 2024 | Zymfentra |
| Intuitive Surgical, INC. | $22.00 | 2022 | |
| Olympus America INC. | $19.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.94 | 2023 | |
| Mylan Institutional INC. | $18.43 | 2023 | Hulio |
| Endo Pharmaceuticals INC. | $15.64 | 2021 | |
| Alfasigma USA, INC. | $15.30 | 2020 | |
| Fresenius Kabi USA, LLC | $14.76 | 2023 | Idacio |
| Allergan, INC. | $14.50 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.39 | 2022 | |
| Phathom Pharmaceuticals, INC. | $6.78 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.